Ipamorelin vs tesamorelin: an approved medicine with a label against an unapproved compound with two trials
One has phase 3 trials, a defined dose and a documented side-effect profile for a single indication; the other has a reputation. What each record shows, and why no study compares them.
At a glance
The short answer
Ipamorelin and tesamorelin are compared because both raise growth hormone, but only one is a medicine. Tesamorelin (Egrifta) is a stabilised GHRH analogue approved in the United States in 2010 to reduce abdominal fat in people with HIV-associated lipodystrophy, with phase 3 trials behind that single indication. Ipamorelin is a ghrelin-receptor agonist that was never approved and has two human trials.
No study compares them directly. Tesamorelin's approved dose, 2 milligrams daily by subcutaneous injection, is the only regulator-reviewed dose of any compound in this comparison, and it applies to one narrow population.
Ipamorelin vs tesamorelin in two minutes
One is a medicine. Tesamorelin is FDA-approved, since 2010, for one use: reducing excess abdominal fat in adults with HIV who have lipodystrophy. It has phase 3 trials, a label, a defined dose of 2 milligrams daily, and a documented side-effect profile. Ipamorelin has none of those.
Different receptors. Tesamorelin is a GHRH analogue with substitutions that protect it from breakdown; ipamorelin acts on the ghrelin receptor. Both release growth hormone from the pituitary.
The catch. Tesamorelin's evidence is in a specific population for a specific outcome. Its use for general fat loss or body composition in people without HIV is off-label and, in trials that exist, modest. Ipamorelin has no efficacy trial at all.
Head to head. Nothing. No indexed study compares them.
Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.
Side by side, from each record
Each column states what that compound's own record says. Nothing is inferred across columns.
| Ipamorelin | Tesamorelin | |
|---|---|---|
| Class | ghrelin mimetics | ghrh analogs |
| Target | ghrelin receptor (GHS-R1a) agonist | GHRH receptor agonist, stabilised GHRH analog |
| Evidence tier | Human clinical trial | Approved label |
| Indexed publications | 63 | 115 |
| Randomized controlled trials | 2 | 22 |
| Human studies in ledger | 2 | 19 |
| Approval status | not approved · max phase 2 | approved (2010) |
What differs, point by point
| Ipamorelin | Tesamorelin | |
|---|---|---|
| Class | Ghrelin mimetic (GHS-R1a agonist) | GHRH analogue, stabilised |
| Approval | Never approved | FDA 2010 (Egrifta), HIV-associated lipodystrophy; also approved in some other jurisdictions |
| Approved dose | None | 2 mg subcutaneously once daily (label) |
| Half-life | About 2 hours | About 26 to 38 minutes |
| Human evidence | 2 trials: pharmacokinetics; failed ileus trial | Phase 3 trials in HIV lipodystrophy; smaller trials in other populations |
| Documented side effects | Almost none documented; two trials | Injection-site reactions, joint pain, fluid retention, raised IGF-1 and glucose effects, on the label |
| Cost and access | Unregulated research-chemical market | Prescription medicine; high list price |
| Sport status | WADA S2 | WADA S2 |
Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.
Studies that name both compounds
Indexed papers whose abstracts name both compounds, quoted. Read the design line on each card: naming both is not the same as comparing them.
How the two are discussed as choices
The comparison usually arises for fat loss, and here the asymmetry matters. Tesamorelin has trials showing reduced visceral fat in a population with a specific metabolic condition, with a label that lists what went wrong in those trials. Ipamorelin has a reputation, from animal and volunteer pharmacology, and no outcome trial. A reader choosing between them is choosing between an approved drug used off-label and an unapproved compound used on faith; the label is also the reason tesamorelin's cautions, on glucose, IGF-1 and active malignancy, are known rather than theoretical. The two are also combined, as the tesamorelin and ipamorelin stack, on the same GHRH-plus-ghrelin logic as other blends; no study has tested that pair.
Editorial synthesis Written from general pharmacology, the development record and what is commonly reported; not a cited finding. Cited findings on this page carry their own tier.
Open questions
- No study compares the two for any outcome.
- Tesamorelin's effect outside HIV-associated lipodystrophy is off-label and modestly evidenced.
- Ipamorelin has no efficacy trial in any population.
Questions people ask
Is tesamorelin FDA approved?
Yes, since 2010, as Egrifta, for reducing excess abdominal fat in adults with HIV-associated lipodystrophy. Other uses are off-label.
Is ipamorelin FDA approved?
No. It has never been approved for any use.
Which is more effective for fat loss?
Tesamorelin has phase 3 trials showing reduced visceral fat in people with HIV lipodystrophy; ipamorelin has no efficacy trial. In people without HIV, tesamorelin's effect is off-label and modest in the trials that exist; no comparison has been run.
What is the approved tesamorelin dose?
2 milligrams by subcutaneous injection once daily, for its approved indication. No dose of ipamorelin has been approved or established.
Can they be combined?
Communities do, on GHRH-plus-ghrelin logic. No study has tested the pair.
Are both prohibited in sport?
Yes, both under WADA S2, at all times.
Reference card
- Comparison
- Ipamorelin vs Tesamorelin
- Class
- ghrelin mimetics · ghrh analogs
- Target
- ghrelin receptor (GHS-R1a) agonist · GHRH receptor agonist, stabilised GHRH analog
- Evidence tier
- Human clinical trial · Approved label
- Indexed publications
- 63 · 115
- Randomized controlled trials
- 2 · 22
- Human studies in ledger
- 2 · 19
- Approval status
- not approved · max phase 2 · approved (2010)
- Studies naming both
- 0 indexed papers
Each figure comes from that compound's own record. Print or save this card with its date.
Last reviewed and what changed
- · Reviewed by Adam Mirando, PharmD, on 2026-09-29.
- · Record created from measured demand (research/queue and the ipamorelin intent map); cross-class comparison written editorially; no head-to-head study exists and the page says so.